Skip to main content
    C

    Cumberland Pharmaceuticals Inc (CPIX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $5.21
    -0.67 (-11.39%)

    Market Cap: $88.16M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Cumberland Pharmaceuticals Inc (CPIX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Cumberland Pharmaceuticals are Cardiol Therapeutics (CRDL), Talphera (TLPH) and Journey Medical (DERM). By market cap, Cumberland Pharmaceuticals ranks 10th of the 13 companies on this page; Canopy Growth (CGC) is the largest at $252.32M.

    Peer Comparison

    CPIX's revenue growth of -74.0% is below the peer median of 0.0%. It yields 28.79%, while the median peer pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Cumberland Pharmaceuticals (CPIX)$88.16MN/A3.1x148.6%N/A-74.0%28.79%
    Cardiol Therapeutics Inc Class A (CRDL)$127.69MN/AN/A0.0%N/A0.0%0.00%
    Talphera Inc. (TLPH)$47.07MN/AN/A0.0%N/A0.0%0.00%
    Journey Medical Corp (DERM)$122.24MN/A1.5x-7.3%-2.8%7.6%0.00%
    Organogenesis Holdings Inc (ORGO)$105.15MN/A0.3x-38.5%-66.3%-69.9%0.00%
    SIGA Technologies Inc (SIGA)$196.88M475.0xN/A1.3%N/A-49.7%0.00%
    Akebia Ther (AKBA)$131.67MN/A0.6x-22.6%-38.9%-37.2%0.00%
    InterCure Ltd. (INCR)$49.17MN/AN/A-13.2%N/A23.9%0.00%
    OrganiGram Holdings Inc (OGI)$116.93MN/A0.4x28.0%-1.2%49.4%0.00%
    Scynexis Inc (SCYX)$31.95MN/A1.8x-53.5%-16.4%-82.8%0.00%
    Anika Therapeutics Inc (ANIK)$179.50M18.7x1.4x-1.4%N/A10.0%0.00%
    Lifecore Biomedical Inc. (LFCR)$243.36MN/AN/A-66.8%N/A-18.6%0.00%
    Canopy Growth Corp (CGC)$252.32MN/AN/A-88.1%N/A22.0%0.00%
    Peer median$124.96M246.9x1.0x-10.3%-16.4%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Cumberland Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Drug Manufacturers - Specialty & Generic.

    CompanyAboutPeers
    Cardiol Therapeutics Inc Class A (CRDL)
    Cardiol Therapeutics Inc., a clinical-phase biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment...
    CRDL competitors
    Talphera Inc. (TLPH)
    Talphera Inc. is a pioneering biotechnology company dedicated to advancing peptide-based therapies for rare diseases and significant unmet medical needs.
    TLPH competitors
    Journey Medical Corp (DERM)
    Dermira, Inc., a biopharmaceutical company, develops and markets therapies for patients with dermatological diseases in the United States.
    DERM competitors
    Organogenesis Holdings Inc (ORGO)
    Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports...
    ORGO competitors
    SIGA Technologies Inc (SIGA)
    SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health safety and infectious disease markets in the United States.
    SIGA competitors
    Akebia Ther (AKBA)
    Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease.
    AKBA competitors
    InterCure Ltd. (INCR)
    Syneos Health, Inc., a contract research organization, provides various clinical development services for the medical device and biopharmaceutical industries...
    OrganiGram Holdings Inc (OGI)
    Organigram Holdings Inc. produces and sells cannabis and cannabis-derived products in Canada. The company is headquartered in Moncton, Canada.
    OGI competitors
    Scynexis Inc (SCYX)
    SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States.
    SCYX competitors
    Anika Therapeutics Inc (ANIK)
    Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally.
    ANIK competitors
    Lifecore Biomedical Inc. (LFCR)
    Lifecore Biomedical, Inc., is an integrated contract development and manufacturing organization in the United States and internationally.
    LFCR competitors
    Canopy Growth Corp (CGC)
    Canopy Growth Corporation is engaged in the production, distribution and sale of cannabis and hemp-based products for recreational and medical purposes...
    CGC competitors

    Frequently Asked Questions About CPIX

    Who are Cumberland Pharmaceuticals' main competitors?

    The companies most similar to Cumberland Pharmaceuticals include Cardiol Therapeutics (CRDL), Talphera (TLPH), Journey Medical (DERM), Organogenesis Holdings (ORGO) and SIGA Technologies (SIGA), listed from the closest match.

    Who is Cumberland Pharmaceuticals' biggest competitor?

    Canopy Growth (CGC) is the largest of the similar companies at $252.32M; Cardiol Therapeutics (CRDL) is the closest match by business profile, size, sector and industry.

    How does CPIX stock compare with its competitors?

    CPIX's P/S is 3.1x against a peer median of 1.0x; its net margin is 148.6% against a peer median of -10.3%.

    Which of Cumberland Pharmaceuticals' competitors pays a higher dividend?

    Cumberland Pharmaceuticals has a forward dividend yield of 28.79%. None of the similar companies with available yields has a higher forward dividend yield.

    Is Cumberland Pharmaceuticals bigger than its competitors?

    No. Cumberland Pharmaceuticals is 10th by market cap among the 13 companies on this page; the largest is Canopy Growth (CGC) at $252.32M.